Reduce total cost of oncology care
Support earlier identification before deterioration.
At-home FBC testing on Algocyte Proxima for earlier risk stratification and remote haematological toxicity escalation.
Meet Algocyte ProximaFor payors & value-based care
Oncology emergencies caught earlier.
Algocyte can give payors and value-based care organisations a future longitudinal oncology monitoring layer that may reduce avoidable admissions and total cost of care.
POTENTIAL FOR
3.5×
Projected system ROI in oncology from avoided escalations
Lower
Oncology total cost of care
(modelled)
Fewer
Admissions and emergency department visits
(evaluative)
The problem
Periodic monitoring is the wrong cost curve.
Delayed detection
Episodic monitoring lets complications surface only after clinical deterioration.
Limited risk visibility
Claims-based risk management sees the bill, not the biology.
High cost
Acute-care interventions cost orders of magnitude more than early intervention.
Fragmented data
Clinical signal is split across providers and systems.
Support value-based care delivery
Potential better outcomes at projected lower costs.
Across oncology cohorts into existing care management workflows.
Inside Health HubHow a payor pilot runs.
01
Pick the cohort
We co-select the oncology population where impact is most measurable.
02
Deploy at home
Devices ship to members; onboarding is fully remote.
03
Stratify regularly
AI risk scoring across longitudinal FBC and symptom data.
04
Reconcile outcomes
Quarterly review against avoided admissions and contracted endpoints.
Built for everyone in the room.
Bring regular immune monitoring to users and patients.
Book a 20-minute briefing with our team to see Algocyte in action.